Our team

Scientific leadership, clinical expertise and patient advocacy advancing therapies for GABA-related neurological disorders.

Alexander Rotenberg, MD, PhD

Co-Founder

Joseph J. Volpe Chair and Professor of Neurology at Harvard Medical School and Boston Children’s Hospital where he directs the Epilepsy Monitoring Unit and the Neuromodulation Program. Physician-scientist specializing in epilepsy and neural circuit dysfunction. He provides scientific leadership for Galibra’s therapeutic strategy targeting GABA-related neurological disorders.

Henry Lee, MPhil, PhD

Co-Founder

Neuroscientist at Harvard Medical School and Boston Children’s Hospital specializing in inhibitory neurotransmission and translational neuroscience. His research focuses on mechanisms regulating GABAergic signaling and neurological disease. Leads preclinical development of Galibra’s gene therapy programs targeting disorders of GABA metabolism.

Amber Freed, MAcc

Chief Development Officer

Rare disease parent, Founder and CEO of SLC6A1 Connect, a global nonprofit advancing research for SLC6A1-related disorders. Former equity research analyst at Janus Henderson Investors and RK Capital Management. Parent of a child with SLC6A1 deficiency. Leads development strategy and patient engagement for Galibra.

Brad Hoffman, MBA

Chief Financial Officer

Rare disease parent, Founder and President of the SSADH Association and former President and CEO of Arandell Corporation. Parent of a child with SSADH deficiency. Brings more than 30 years of executive leadership experience and leads business development and strategic partnerships for Galibra.

Phillip Pearl, MD

Clinical Study Advisor

William G. Lennox Chair and Professor of Neurology at Harvard Medical School and Boston Children’s Hospital and Director of Epilepsy and Clinical Neurophysiology. International expert in pediatric epilepsy and metabolic neurological disorders, including SSADH deficiency.

Guangping Gao, PhD

AAV Manufacturing Advisor

Penelope Booth Rockwell Professor at UMass Chan Medical School and Director of the Horae Gene Therapy Center. Pioneer in AAV gene therapy and discovery of multiple viral vector serotypes widely used in gene therapy research and clinical development.